A citation-based method for searching scientific literature

Josep Tabernero, Paulo M Hoff, Lin Shen, Atsushi Ohtsu, Manish A Shah, Karen Cheng, Chunyan Song, Haiyan Wu, Jennifer Eng-Wong, Katherine Kim, Yoon-Koo Kang. Lancet Oncol 2018
Times Cited: 204



J Randolph Hecht, Yung-Jue Bang, Shukui K Qin, Hyun C Chung, Jianming M Xu, Joon O Park, Krzysztof Jeziorski, Yaroslav Shparyk, Paulo M Hoff, Alberto Sobrero, Pamela Salman, Jin Li, Svetlana A Protsenko, Zev A Wainberg, Marc Buyse, Karen Afenjar, Vincent Houé, Agathe Garcia, Tomomi Kaneko, Yingjie Huang, Saba Khan-Wasti, Sergio Santillana, Michael F Press, Dennis Slamon. J Clin Oncol 2016
Times Cited: 357




List of shared articles



Times cited

Cortactin and HER2 as potential markers for dural-targeted therapy in advanced gastric cancer.
Jun Wei, Yimin Wang, Bo Xie, Jiachi Ma, Yaguo Wang. Clin Exp Med 2022
1

Gastroesophageal adenocarcinoma in older adults: A comprehensive narrative review of management by the Young International Society of Geriatric Oncology.
Mark A Baxter, Joana Marinho, Enrique Soto-Perez-de-Celis, Maria Grazia Rodriquenz, Sukeshi Patel Arora, Wendy Chan Wing Lok, Yung-Yu Shih, Gabor Liposits, Shane O'Hanlon, Russell D Petty. J Geriatr Oncol 2022
0


Efficacy and safety of targeted drugs in advanced or metastatic gastric and gastroesophageal junction cancer: A network meta-analysis.
Hongxia Gong, Yun Su, Lixia Zhao, Li Ma, Liying Zhang, Liangying Hou, Tingting Li, Shiwei Niu, Han Zhang, Chenghao Li,[...]. J Clin Pharm Ther 2022
1

HER2 in gastric adenocarcinoma: where do we stand today?
Khalil El Gharib, Makram Khoury, Hampig Raphael Kourie. Per Med 2022
0


Trastuzumab with trimodality treatment for oesophageal adenocarcinoma with HER2 overexpression (NRG Oncology/RTOG 1010): a multicentre, randomised, phase 3 trial.
Howard P Safran, Kathryn Winter, David H Ilson, Dennis Wigle, Thomas DiPetrillo, Michael G Haddock, Theodore S Hong, Lawrence P Leichman, Lakshmi Rajdev, Murray Resnick,[...]. Lancet Oncol 2022
14

Current status and future perspectives in HER2 positive advanced gastric cancer.
G Roviello, M Catalano, L F Iannone, L Marano, M Brugia, G Rossi, G Aprile, L Antonuzzo. Clin Transl Oncol 2022
1

Pharmaceutical advances in the treatment of gastric adenocarcinoma.
Jane E Rogers, Matheus Sewastjanow D Silva, Rebecca E Waters, Jaffer A Ajani. Expert Opin Pharmacother 2022
0

Esophageal cancer: emerging therapeutics.
Jane E Rogers, Matheus Sewastjanow-Silva, Rebecca E Waters, Jaffer A Ajani. Expert Opin Ther Targets 2022
4

Personalized Treatment of Advanced Gastric Cancer Guided by the MiniPDX Model.
Jianzheng Wang, Jinxi Huang, Hui Wang, Wei Yang, Qiwen Bai, Zhentao Yao, Qingli Li, Huifang Lv, Beibei Chen, Caiyun Nie,[...]. J Oncol 2022
0

Editorial: Molecular Biomarkers for Gastric Cancer.
Xinqiang Hong, Fenglin Liu. Front Oncol 2022
1


The dawn of precision medicine in diffuse-type gastric cancer.
Akira Ooki, Kensei Yamaguchi. Ther Adv Med Oncol 2022
3

Chemorefractory Gastric Cancer: The Evolving Terrain of Third-Line Therapy and Beyond.
Maria Alsina, Josep Tabernero, Marc Diez. Cancers (Basel) 2022
1

Retrospective Study on the Efficacy and Safety of Pyrotinib-Based Therapy for HER2-Positive Nonbreast Advanced Solid Tumors.
Jianzheng Wang, Baiwen Zhang, Xiaojiao Cheng, Qingli Li, Huifang Lv, Caiyun Nie, Beibei Chen, Weifeng Xu, Jing Zhao, Yunduan He,[...]. J Oncol 2022
0

Analysis of a Real-World Progression Variable and Related Endpoints for Patients with Five Different Cancer Types.
Aracelis Z Torres, Nathan C Nussbaum, Christina M Parrinello, Ariel B Bourla, Bryan E Bowser, Samuel Wagner, David C Tabano, Daniel George, Rebecca A Miksad. Adv Ther 2022
0

Molecular pathogenesis and emerging targets of gastric adenocarcinoma.
Abby Ivey, Hillary Pratt, Brian A Boone. J Surg Oncol 2022
3

Evolution of predictive and prognostic biomarkers in the treatment of advanced gastric cancer.
Nicole M Myer, Kohei Shitara, Hyun C Chung, Florian Lordick, Ronan J Kelly, Zsolt Szabo, Z Alexander Cao, Stephen Leong, David H Ilson, Wilko Weichert. J Cancer Res Clin Oncol 2022
0

Putative Clinical Potential of ERBB2 Amplification Assessment by ddPCR in FFPE-DNA and cfDNA of Gastroesophageal Adenocarcinoma Patients.
Elisa Boldrin, Marcodomenico Mazza, Maria Assunta Piano, Rita Alfieri, Isabella Monia Montagner, Giovanna Magni, Maria Chiara Scaini, Loretta Vassallo, Antonio Rosato, Pierluigi Pilati,[...]. Cancers (Basel) 2022
0

Therapeutic Advances and Challenges in the Management of HER2-Positive Gastroesophageal Cancers.
Jeremy Chuang, Samuel Klempner, Kevin Waters, Katelyn Atkins, Joseph Chao, May Cho, Andrew Hendifar, Alexandra Gangi, Miguel Burch, Pareen Mehta,[...]. Diseases 2022
0

A Case Report of Immunotherapy-Resistant MSI-H Gastric Cancer with Significant Intrapatient Tumoral Heterogeneity Characterized by Histologic Dedifferentiation.
Nikhila Kethireddy, Leonidas Arvanitis, Janine LoBello, Yanghee Woo, Szabolcs Szelinger, Joseph Chao. J Clin Med 2022
0

Stem Cell Biomarkers and Tumorigenesis in Gastric Cancer.
Kenly Wuputra, Chia-Chen Ku, Jia-Bin Pan, Chung-Jung Liu, Yi-Chang Liu, Shigeo Saito, Kohsuke Kato, Ying-Chu Lin, Kung-Kai Kuo, Te-Fu Chan,[...]. J Pers Med 2022
0

From Anti-HER-2 to Anti-HER-2-CAR-T Cells: An Evolutionary Immunotherapy Approach for Gastric Cancer.
Jiangang Sun, Xiaojing Li, Peng Chen, Yongshun Gao. J Inflamm Res 2022
0


Deviating HER2 test results in gastric cancer: analysis from the prospective multicenter VARIANZ study.
Katharina Kolbe, Ivonne Haffner, Katrin Schierle, Dieter Maier, Birgitta Geier, Birgit Luber, Hendrik Bläker, Christian Wittekind, Florian Lordick. J Cancer Res Clin Oncol 2022
0

Antibody-drug conjugates to treat gastric cancer.
Shigehiro Koganemaru, Kohei Shitara. Expert Opin Biol Ther 2021
5

First-line pembrolizumab/placebo plus trastuzumab and chemotherapy in HER2-positive advanced gastric cancer: KEYNOTE-811.
Hyun Cheol Chung, Yung-Jue Bang, Charles S Fuchs, Shu-Kui Qin, Taroh Satoh, Kohei Shitara, Josep Tabernero, Eric Van Cutsem, Maria Alsina, Zhu Alexander Cao,[...]. Future Oncol 2021
50

Potential Molecular Targets in the Setting of Chemoradiation for Esophageal Malignancies.
Salma K Jabbour, Terence M Williams, Mutlay Sayan, Eric D Miller, Jaffer A Ajani, Andrew C Chang, Norman Coleman, Wael El-Rifai, Michael Haddock, David Ilson,[...]. J Natl Cancer Inst 2021
1


Current treatment and recent progress in gastric cancer.
Smita S Joshi, Brian D Badgwell. CA Cancer J Clin 2021
177


Is advanced esophageal adenocarcinoma a distinct entity from intestinal subtype gastric cancer? Data from the AGAMENON-SEOM Registry.
Felipe Alvarez-Manceñido, Paula Jimenez-Fonseca, Alberto Carmona-Bayonas, Virginia Arrazubi, Raquel Hernandez, Juana M Cano, Ana Custodio, Carles Pericay Pijaume, Gema Aguado, Nieves Martínez Lago,[...]. Gastric Cancer 2021
3

Changes in the therapeutic landscape of oesophago-gastric cancers.
Nina Fokter Dovnik, Elizabeth C Smyth. Curr Opin Oncol 2021
0

Human epidermal growth factor receptor 2 (HER2) in advanced gastric cancer: where do we stand?
Giandomenico Roviello, Giuseppe Aprile, Alberto D'Angelo, Luigi Francesco Iannone, Franco Roviello, Karol Polom, Enrico Mini, Martina Catalano. Gastric Cancer 2021
6

Personalized therapeutic strategies in HER2-driven gastric cancer.
Stefano Ughetto, Cristina Migliore, Filippo Pietrantonio, Maria Apicella, Annalisa Petrelli, Laura D'Errico, Stefania Durando, Daniel Moya-Rull, Sara E Bellomo, Sabrina Rizzolio,[...]. Gastric Cancer 2021
1

Trastuzumab deruxtecan in HER2-positive metastatic breast cancer and beyond.
Jose Perez, Laia Garrigós, Maria Gion, Pasi A Jänne, Kohei Shitara, Salvatore Siena, Javier Cortés. Expert Opin Biol Ther 2021
6

HER2 Expression, Test Deviations, and Their Impact on Survival in Metastatic Gastric Cancer: Results From the Prospective Multicenter VARIANZ Study.
Ivonne Haffner, Katrin Schierle, Elba Raimúndez, Birgitta Geier, Dieter Maier, Jan Hasenauer, Birgit Luber, Axel Walch, Katharina Kolbe, Jorge Riera Knorrenschild,[...]. J Clin Oncol 2021
24


Biomarker-targeted therapies for advanced-stage gastric and gastro-oesophageal junction cancers: an emerging paradigm.
Yoshiaki Nakamura, Akihito Kawazoe, Florian Lordick, Yelena Y Janjigian, Kohei Shitara. Nat Rev Clin Oncol 2021
34

Trastuzumab deruxtecan for the treatment of HER2-positive gastric cancer.
Saori Mishima, Kohei Shitara. Expert Opin Biol Ther 2021
2

HER2-targeted therapies in gastric cancer.
Yinxing Zhu, Xuedan Zhu, Xiaowei Wei, Cuiju Tang, Wenwen Zhang. Biochim Biophys Acta Rev Cancer 2021
17

Novel HER2-Directed Treatments in Advanced Gastric Carcinoma: AnotHER Paradigm Shift?
Angela Dalia Ricci, Alessandro Rizzo, Fabiola Lorena Rojas Llimpe, Francesca Di Fabio, Dario De Biase, Karim Rihawi. Cancers (Basel) 2021
33

Bone Metastases from Gastric Cancer: What We Know and How to Deal with Them.
Angelica Petrillo, Emilio Francesco Giunta, Annalisa Pappalardo, Davide Bosso, Laura Attademo, Cinzia Cardalesi, Anna Diana, Antonietta Fabbrocini, Teresa Fabozzi, Pasqualina Giordano,[...]. J Clin Med 2021
4

Hopes and failures in front-line advanced HER2-positive gastric cancer therapy.
Fanming Kong, Yang Yao, Renfen Deng, Xiaojiang Li, Yingjie Jia. Anticancer Drugs 2021
0

Phase I study of the recombinant humanized anti-HER2 monoclonal antibody-MMAE conjugate RC48-ADC in patients with HER2-positive advanced solid tumors.
Yingying Xu, Yakun Wang, Jifang Gong, Xiaotian Zhang, Zhi Peng, Xinan Sheng, Chenyu Mao, Qingxia Fan, Yuxian Bai, Yi Ba,[...]. Gastric Cancer 2021
15

Targeted and immunotherapy in the era of personalised gastric cancer treatment.
Silvia Catanese, Florian Lordick. Best Pract Res Clin Gastroenterol 2021
7

Roles of Nrf2 in Gastric Cancer: Targeting for Therapeutic Strategies.
Tahereh Farkhondeh, Ali Mohammad Pourbagher-Shahri, Mohsen Azimi-Nezhad, Fatemeh Forouzanfar, Aranka Brockmueller, Milad Ashrafizadeh, Marjan Talebi, Mehdi Shakibaei, Saeed Samarghandian. Molecules 2021
6


Evolving treatment paradigms in esophageal cancer.
Ilit Turgeman, Irit Ben-Aharon. Ann Transl Med 2021
6